However, it has been reported that the use of SGLT2 inhibitors significantly reduces the development of CI-AKI, particularly in patients with acute myocardial infarction undergoing pPCI and type 2 diabetes [38,39]. Here, SLC5A2 is linked to acute kidney injury.